IgG as demonstrated by ELISA, size-exclusion chromatography and sucrose gradient ultracentrifugation. The formation of IgAl-IgG complexes may affect the serum level of IgAl by reducing the rate of its elimination and catabolic degradation by the liver.
IgAN nephropathy (IgAN) is the most common glomerulonephritis worldwide [1] [2] [3] [4] . The disease is characterized by deposition of IgA of the IgAl subclass in the kidney mesangia in all patients, and by elevated serum levels of IgA, IgAl-immune complexes (IC) and IgAl-rheumatoid factor (IgAl-RF) in approximately one-half of patients [1] [2] [3] [4] [5] [6] . Increased serum levels of IgAl and IgAl-IC, with deposition in the mesangium and skin, have been described also in diseases related to IgAN, such as dermatitis herpetiformis (DH) and Henoch-Schönlein purpura (I-iSP) [7, 8] . Although elevated levels of IgA, IgA-IC and/or IgA-RF have been detected in many other diseases (such as AIDS, IgA multiple myeloma, rheumatoid arthritis [RA], psoriasis, and Kawasaki's, Behcet's, and celiac diseases), IgA mesangial deposits are usually absent [9] [10] [11] [12] ; in alcoholic liver disease and systemic lupus erythematosus (SLE) such deposits arc relatively frequent [13, 14] . Mechanisms for the mesangial deposition of IgAl preferentially in patients with IgAN, DH, and HSP cornpared to patients with other diseases with elevated IgA, IgA-IC, and IgA-RF are unknown [3, 15] .
Pathogenesis of IgAN may be associated with overproduction of polyclonal or antigen-specific IgAl and/or its defective clearance [reviewed in 4, 15, 16] . However, mere overproduction of IgAl due to excessive stimulation is unlikely to be the cause of IgAl-IC deposition in tissues: high plasma levels of IgAl in multiple myeloma do not result in tissue deposition and IgA-IC are found only rarely [11] . Furthermore, patients with AIDS share several common features with patients with IgAN, such as increased serum levels of IgAl, IgAl-RF and IgAl-IC that apparently are composed of identical components (IgAl-IgG-C3) [9, 17, 18] ; however, tissue deposition of IgAl is a prominent feature in patients only with IgAN, not with AIDS [10, 17, As demonstrated in vivo (both in mice and primates) and in vitro (human hepatoma cell line Hep G2) the liver accounts for most of the catabolism of IgA1 [19] [20] [21] [22] . These studies revealed that hepatocytes and, to a lesser degree, nonparenchymal cells internalize and degrade IgA1 [20] . The asialoglycoprotein receptor (ASGP-R), which recognizes terminal galactose (Gal) residues on glycoproteins, was identified as the principal IgA receptor [19, 20] , and a clear preference for IgAl and especially its carbohydrate-rich hinge region was noted [20, 23] . Studies performed in patients with IgAN suggest that alterations in IgAl receptors are unlikely because radiolabeled IgAl injected into patients with IgAN was cleared normally [24] . The second possibility, aberrant glycosylation pattern of the glycan moiety on IgAl from IgAN patients, has been suggested in several recent studies [25] [26] [27] [28] [29] [30] Clinical presentation of IgA nephropathy and other renal diseases was evaluated according to duration from clinically apparent onset, maximal and current proteinuria, hematuria, serum creatinine concentration, rate of increase of serum creatinine (expressed as the mean increase per year; the difference between the first and last serum creatinine was divided by the number of years of follow-up), and blood pressure. Renal biopsy findings were evaluated semiquantitatively according to the degree of mesangial hypercellularity and sclerosis, percentage of sclerotic glomeruli, presence of extracapillary proliferation, grade of tubular atrophy and interstitial sclerosis and degree of arteriosclerosis. The extent of IgA, IgG, 1gM and C3 in mesangial deposits was evaluated by immunofluorescence microscopy [29] .
Isolation of serum and myeloma IgAl
IgAl from sera of IgAN patients and controls was isolated by affinity chromatography on a column with monoclonal anti-IgAl antibody (Clone NI 69-11, Nordic, Tilburg, The Netherlands) immobilized on CNBr-activated Sepharose 4B (Sigma Chemical Company, St. Louis, MO, USA). The specificity of this reagent was extensively tested in a battery of immunochemical tests [31, 32] . IgAl was eluted from the affinity column at pH 3. Following neutralization with sodium bicarbonate, the solution was desalted by gel-filtration on a column of Sephadex G25, equilibrated with phosphate-buffered saline [33] . The results indicated that the first set of preparations contained human IgG. Therefore, in the second set IgAl isolated by this procedure was further purified by affinity chromatography on a column with immobilized staphylococcal protein G (Sigma) to remove IgG contaminants.
Monomeric and polymeric IgAl and polymeric IgA2 myeloma proteins were isolated by standard methods [34] which included ammonium sulfate precipitation, gel-filtration, starch-gel electrophoresis [34] , affinity chromatography on jacalin [29, 35] and immunoabsorption [34] . Jacalin conjugated to agarose (Pierce, Rockfort, IL, USA), and protein G immobilized to agarose (Sigma Chemical Company) were purchased.
Modification of the carbohydrate moiety of IgA N-acetylneuraminic acid (NeuNAc) residues linked to Gal or N-acetylgalactosamine (GaINAc) on IgAl were cleaved with neuraminidase from Vihrio cholerae (Boehringer-Mannheim, Indianapolis, IN, USA) or neuraminidase cloned from Clostridium perfringens and expressed in Escherichia coli (New England BioLabs, Beverly, MA, USA). Gal residues linked to GaINAc in the hinge region of IgAl were cleaved either with /3-galactosidase from bovine testes (Boehringer-Mannheim) which hydrolyzes /31,3 linkages substantially faster than /31,4 or /31,6 linkages to G1cNAc [36] or with highly specific /31,3-galactosidase from Xanthomonas manihotis (New England BioLabs). IgAl preparations de-galactosylated in the hinge region were separated from galactosylated IgAl by affinity chromatography on a column of immobilized jacalin (a lectin specific for Gal(/31-3)GaINAc glycans; Pierce, Rockford, IL, USA). Neuraminidase, /31,3 galactosidase from bovine testes or X manihotis and liberated monosaccharides were separated from IgA by gel-filtration through a column of Superdex PG (Pharmacia Biotech, Piscataway, NJ, USA). The effect of glycosidase treatment of IgAl was tested by gas chromatography (see below).
Interactions of biotinylated lectins with serum IgAl
Wells of microtiter plates were coated with F(ab')2 fragment of goat anti-human IgA (a chain-specific; Organon Teknika Corp., Westchester, PA, USA). Following washing and blocking of free active sites with bovine serum albumin (BSA) in PBS (pH 7.3) containing 0.05% Tween 20, the test sera diluted in the same BSA and Tween-containing buffer were added to the wells. After overnight incubation at 4°C, the test sera were removed, wells were washed with Tween-containing buffer, then filled with 100 .tI of sodium acetate buffer, pH 5, containing 10 mU/mi of V. . Titration studies have shown that under conditions described above the optimal dilution of these lectins was 1:500. After subsequent washing, the wells were incubated with avidin-alkaline phosphatase (AP) (1:8000); after additional washings they were incubated with the phosphatase substrate (Avidin-AP and phosphatase substrate were purchased from Sigma). The OD at 405 nm was determined in an ELISA reader (Titertek Multiscan, ICN Biochemicals, Irvine, CA, USA).
We also tested interactions of GaINAc-specific lectins with IgG-IgAl complexes. Wells of microtiter plates were coated with IgG binding staphylococcal proteins A or G. After blocking with BSA-PBS-Tween the wells were incubated with the diluted test serum, then treated with neuraminidase as described above. Reagents used in this study, protein A and protein G were purchased from Sigma.
Size exclusion chromatography of serum proteins
To determine the molecular form of IgAl proteins reacting with GaINAc-specific lectins, sera from IgAN patients and controls were subjected to size exclusion chromatography by HPLC and by preparative ultracentrifugation in sucrose gradient as described [37] . Fractions were tested by ELISA for the content of 1gM, IgAl, IgG and proteins reacting with HAA. HPLC analyses were conducted using Perkin Elmer (Series 10) HPLC equipped with a BioSep-SEC-S3000 column (600 X 7.8 mm; Phenomenex, Torrance, CA, USA) equilibrated with 0.02 M phosphate, 0.05 M Na2SO4, pH 6.7. Biotinylated polyclonal antibodies to 1gM and IgG (both heavy chain-specific) and alkaline phosphatase-conjugated monoclonal anti-IgAl reagent used in the ELISA assay were purchased from Southern Biotechnology (Birmingham, AL, USA).
Carbohydrate analyses
The monosaccharides were determined as trifluoroacetates of methyl-glycosides by gas chromatography [38] , with a few modifications. Aliquots of IgA and IgG preparations (20 and 50 g, respectively) were processed and derivatized with a mixture of 
Radioiodination
Proteins were radiolabeled with carrier-free Na'251 (Amersham Corp., Arlington Hights, IL, USA) by the lactoperoxidase method [39] . The excess free Na1251 was separated from the protein by gel-filtration on a column of Sephadex G25. The radioactivity was determined in Packard model 5110 y spectrometer.
Statistical analyses
Comparison between group means were performed using Student's t-test. P values equal to or less than 0.05 were considered statistically significant.
RESULTS

Deficient galactosylation of IgAl from sera of IgAN patients
IgAl proteins isolated from sera of 11 IgAN patients and 10 healthy volunteers by affinity chromatography on monoclonal anti-IgAl columns were subjected to carbohydrate analyses by gas-liquid chromatography. Results shown in Table 1 indicated a statistically significant (P = 0.0014) difference in the content of Gal but not other monosaccharides. Because immunochemical tests (ELISA) of the purity of the isolated IgAl indicated the presence of IgG, preparations of IgAl from another group of 6 patients and a pooled sample from 50 healthy individuals were absorbed on immobilized protein G to remove IgG. After this step, no significant differences in the Gal content were detected between IgAl from this group of 6 patients and IgAl from all 11 controls. Because of the convincing specificity of the anti-IgAl reagent [321, we considered the possibility that the lgG in IgAl preparations was present in complexes composed of IgAl and IgG (see below). To determine the localization of Gal-deficient site, we used a battery of lectins specific for terminal mono-or oligosaccharides in 0-and N-linked carbohydrate side-chains.
Gal deficiency is restricted to 0-linked glycans of the IgAl hinge region
To eliminate a possible interference by intact IgG molecules in lectin binding and the frequent presence of IgAl RF in IgAN patients' sera, microtiter plates were coated with an F(ab')2 fragment of anti-IgA [5] and incubated with sera from 10 IgAN patients and 10 healthy controls. The bound IgA was analyzed for reactivity with lectins specified in Table 2 . When intact IgAl was allowed to react with these lectins a statistically significant difference between the two groups was noted when Ga1NAc-specific lectins, HAA and CAA, were used (P = 0.0228 and 0.0405, respectively). The binding affinity of HAA and CAA to IgAl from IgAN patients and controls increased when the IgA bound to the F(ab')2 fragment of anti-IgA in wells of microtiter plate was incubated with neuraminidase in acetate buffer, pH 5. We have determined that this procedure does not alter the amount of IgAl bound in wells. The differences of the HAA and CAA binding to de-sialylated IgAl from IgAN patients and controls were greater than those observed when these lectins bind to intact IgAl from both groups (P = 0.0036 and 0.0085) ( Table 2) . Furthermore, the removal of sialic acid enhanced interactions of IgAl from IgAN patients and controls with additional lectins which did not differ in their ability to bind intact IgA from both groups. Statistically significant differences in binding to IgAl from both groups were observed when de-sialylated serum IgA was incubated with GalNAc-specific lectins HPA (P = 0.0298) and BPA (P = 0.004; Table 2 ). Other lectins, including some with putative GalNAc specificity, did not display significant binding differences between the two groups. Because Ga1NAc occurs only in oligosaccharides of the hinge region of IgAl (and not in IgA2 or IgG) [40] , we concluded that the enhanced reactivity of GalNAc-specific lectins is due to the deficiency of Gal in the 0-linked side-chains of the hinge region of IgAl. Structural studies have shown that glycans in the hinge region of IgAl are present as mono-di-tn-and tetrasaccharides [41] , linked to serine (Fig. 1) . Gas chromatographic analyses and lectin studies of IgAl proteins from IgAN patients and controls indicated variations in the relative proportion of these structures. Increased reactivity of GalNAc-specific lectins with intact or de-sialylated IgAl from IgAN patients suggest increased proportion of structures containing mono-or disaccharide with terminal NeuNAc (Fig. 1, structures D and E) . To confirm the relationship between the structure of IgAl hinge region glycans and binding of GalNAc-specific lectins to IgAl from IgAN sera, several IgAl myeloma proteins were subjected to sequential treatment with neuraminidase and f31,3-galactosidase (to remove NeuNAc and I3Gal linked to GalNAc) and examined for their binding with lectins. The native IgAl myeloma protein (Kni) reacted with two GalNAc-specific lectins (HAA and HPA) relatively poorly ( Table 3 ). The binding substantially increased after removal of NeuNAc and even more after removal of NeuNAc and Gal. Similar results were obtained with five other myeloma proteins that were allowed to react with I-IAA or CAA (data not shown). Furthermore, partial removal of the Gal from hinge region glycans decreased the binding of the IgAl myeloma protein to agarose-immobilized AlA (jacalin), a lectin specific to Gal(1-3)GaINAc (Fig. 2) . This observation suggested that Galdeficient IgAl from IgAN patients should bind to jacalin less effectively than IgAl from controls, as previously reported 25, 26] . In the present study the decreased binding of biotinylated jacalin to intact or de-sialylated IgAl from IgAN patients was apparent. However, the difference between the jacalin binding to IgAl from patients and controls was not statistically significant (Table 2 ). This finding may be associated with a relatively low avidity of jacalin toward degalactosylated IgA under the conditions of this assay.
Increased reactivity of IgA from IgAN patients with
GaINAc-specific lectins De-sialylated IgA from sera of 81 IgAN patients bound biotinlabeled lectin HAA more effectively than did de-sialyated IgA from 56 healthy controls (P < 0.0001). Similar results were observed for 67 IgAN patients and 52 controls with second lectin, CAA (P < 0.001). IgAl from sera of patients with IgAN bound these lectins more effectively than did IgAl from patients with mesangial proliferative glomerulonephritis of non-IgA origin (Table 4) , No correlation was found between the magnitude of binding of lectins listed in Table 4 to IgAl and clinical presentation of IgAN: the duration of the disease, maximal and current proteinuria, magnitude of microscopic hematuria, serum creatinine concentration, rate of serum creatinine increase and blood pressure.
Likewise, no correlation was observed between the lectin binding and morphological parameters such as the degree of mesangial hypercellularity, percentage of sclerotic glomeruli, presence of extracapillary proliferation, grade of tubular atrophy and interstitial sclerosis, and the degree of arteriosclerosis. Furthermore, the lectin binding did not correlate with age or gender.
Among 123 patients with IgAN were three members of a single family (mother and two daughters); all three displayed a similarly increased binding of HAA, well above the mean value for the whole group of IgAN patients.
Gal-deficient IgAl is complexed with IgG
The differences in the Gal content of serum IgAl purified by affinity chromatography on immobilized monoclonal anti-IgAl, or by the same procedure with subsequent removal of IgG by protein G, suggested that Gal-deficient IgAl was in immune complexes with IgG. To provide evidence for this contention, microtiter plates were coated with protein A and protein G (both binding IgG), incubated first with sera from IgAN patients or controls and subsequently with biotinylated HAA. IgG bound to protein A and G was complexed with IgAl deficient in Gal because it reacted with GaINAc-specific lectin (HAA) ( Table 5 ). The differences in the amount of HAA bound to IgAl complexed with IgG from IgAN patients and controls were statistically significant (P < 0.01 when bound to protein A; P < 0.001 when bound to protein G).
Gal-deficient IgAl in complexes with IgG was also detected in HPLC fractions obtained by size-exclusion chromatography of serum specimens from IgAN patients and healthy controls. The distribution of IgAl, IgG, 1gM and protein reacting with HAA in these fractions have shown that the highest reactivity with HAA occurred in high molecular mass fractions containing both IgAl and IgG, while the reactivity with fractions containing monomeric IgG or monomeric and dimeric IgA was considerably diminished (Fig. 3) . Analogous results were obtained using fractions of IC-enriched preparations of sera from IgAN patients separated by HPLC and sucrose-density centrifugation (data not shown).
Therefore, we concluded that Gal-deficient IgAl which displays high reactivity with HAA is preferentially complexed with IgG. Although quantitatively different, parallel experiments with sera of normal volunteers yielded similar distribution of IgG, IgA, 1gM and HAA reactivity.
DISCUSSION
We found that IgAl from sera from patients with IgAN is deficient in Gal and that this Gal deficiency occurs in glycans located in the hinge region of the molecule. The hinge region is a IgAl has been reported [65] . The increase in binding of Ga1NAc-specific lectins to 1gM after removal of NeuNAc suggests the presence of structure E, which has been identified in mammalian submaxillary mucins and other glycoproteins [66] . these lectins bound more effectively to de-sialylated IgAl from IgAN patients than controls. These data suggested that IgAl from IgAN patients more frequently contains glycans in which NeuNAc is bound to GaINAc by a2,6 linkages ( Fig. 1, structure E) .
The existence of such a disaccharide would be consistent with the data of gas-chromatographic analyses that showed a decreased content of Gal but an unchanged content of NeuNAc in IgAl from IgAN patients. Consecutive or parallel treatment of IgAl myeloma proteins or IgAl from IgAN patients with neuraminidase and f31,3-galactosidase also further increased the binding of Ga1NAc-specific lectins by serum IgAl from controls and IgAN patients.
The data of our present study indicate that in sera of IgAN patients, as well as in controls, the under-galactosylated IgAl molecules are bound with IgG in high molar mass complexes. This conclusion is based on the following findings: First, carbohydrate analyses of IgAl purified by affinity chromatography on anti-IgAl immunosorbents, with or without subsequent removal of IgG by protein G, revealed Gal-deficient IgAl in the latter preparations. Second, components from sera of IgAN patients and controls incubated in wells of microtiter plates coated with protein A or protein G reacted with lectins specific for GalNAc, indicating the presence of IgA-IgG complexes. The amount of these lectins bound to de-sialylated IgA-IgO complexes was significantly higher in IgAN patients than in controls. Finally, the reactivity with a GalNAc-specific lectin, HAA, was associated mainly with highmolecular mass fractions of human sera separated by size exclusion chromatography on HPLC or by sucrose-gradient ultracentrifugation; free monomeric or dimeric IgA was less reactive. The specificity of IgG antibodies bound in these complexes with IgAl protein was not conclusively determined.
The incomplete galactosylation of hinge region glycans may result from a deficiency or structural aberration of an enzyme fragment of the al heavy chain rich in Pro, Ser, and Thr residues [41] , and contains four to five 0-linked mono-or oligosaccharides [42] [43] [44] . In contrast to many other serum glycoproteins, including IgD, in which four of the five 0-linked side-chains in the hinge region are linked to Thr residues [45] , in IgAl all 0-linked glycan side-chains are attached to Ser [42] . Amino acid sequences similar to that of human IgAl hinge region have not been described in any other glycoprotein and the pattern in IgAl is explained by a recent insertion of this sequence in the phylogenetically older a2 heavy chain [46] .
An abnormal glycosylation of IgAl from IgAN patients was previously reported by several investigators [25] [26] [27] [28] [29] [30] . Some authors [27] reported deficient galactosylation of hinge region glycans in IgAl preparations isolated from serum of IgAN patients and controls by affinity chromatography on immobilized jacalin. Because binding of IgAl to this lectin is mediated by interactions with a disaccharide Gal(f31 -3)GaINAc, molecules lacking j3Gal in hinge region glycans would not be quantitatively recovered by this technique. The fact that these authors [27] were able to detect deficiency of I3Gal in the hinge region of IgAl isolated from sera by affinity chromatography on jacalin can be explained by a limited specificity of jacalin preparations. Heterogeneity of various jacalin preparations, with respect to specificity, and potential differences in the patient population may also account for the results reported earlier.
Localization of undergalactosylated glycans to the hinge region of IgAl was indicated by increased binding of several lectins specific for GalNAc to IgA from serum of IgAN patients. Most of J31,4-GT involved in galactosylation of GIcNAc in N-linked glycans, the properties, structure and regulation of expression of /31,3-GT remains to be clarified. However, by analogy with an extremely rare hematological disorder, the Tn-syndrome, this locus may be highly sensitive to external influences [471. Detailed molecular studies revealed that the enzyme deficiency was not due to deletion of the 131,3-GT gene; instead, inactivation apparently occurs. This has been demonstrated by in vitro treatment of cells deficient in /31,3-GT by demethylating agents such as 5-azacytidin or n-butyrate. After treatment with such agents, enzymatic activity was restored, yielding normally galactosylated 0-linked glycans [47] . On the other hand, detection of deficient galactosylation of hinge region glycans in members of a family with IgAN (mother and two daughters) suggests that the glycosylation defect, and thus also the availability or function of /31,3-GT, may have been genetically predisposed. [50] . Extensive studies indicate that glycan moieties of glycoproteins participate in essential biological functions [51] . With respect to immunoglobulins, modifications of their carbohydrate moiety greatly influence their catabolic rate [21] , binding to receptors on various cell types [19, 20, 48, 52] , the ability of IgG and IgA to activate classical or alternative pathways of the complement cascade [53] [54] [55] [56] , and their capacity to opsonization of bacteria for phagocytosis [56] and inhibition of bacterial adherence [57] . IgAl molecules display a high degree of heterogeneity with respect to the total glycan content, number and type of oligosaccharide side chains, composition of oligosaccharides and terminal monosaccharides, as shown by carbohydrate analyses and lectin reactivities [57, 58] . Such heterogeneity may reflect the variable availability or functional properties of relevant glycosyltransferases. For example, deficiency of Gal in N-linked glycan side chains in IgG molecules from sera of patients with rheumatoid arthritis [60, 61] was proposed to result from a deficiency or functional modification of pl,4-GT, the enzyme responsible for galactosylation of IgG in B cells [62, 63] . Similarly, deficiency of f31,3-GT in lymphocytes or other blood elements in patients with Tn syndrome causes undergalactosylation of cell membrane glycoproteins with 0-linked glycans [47, 64] . We propose that an analogous defect occurs in IgAN patients: IgAl molecules are undergalactosylated due to the deficiency or structural modification of f31,3-GT in IgAl-secreting cells. This undergalactosylated IgAl may avoid uptake and subsequent catabolic degradation mediated by ASGP-R in hepatocytes due to complexing with IgG. Large lgAl-IgG complexes which have escaped the degradative pathway [50] , and are present in increased concentrations in circulation, may be subsequently deposited in the kidney mesangium. Fraction number
